All blog posts
Total 22 results for
Showing 22 out of 22 results
23 November 2022
SANCTION IMPOSED BY THE SPANISH COMPETITION AUTHORITY ON A PHARMA COMPANY FOR MISUSING LITIGATION STRATEGIES REGARDING PATENTS
11 October 2022
Update on the Teva Copaxone EU case. The EU Commission issues a Statement of Objections against Teva over alleged anti-competitive conduct consisting of misuse of divisional patents and a disparagement campaign against its closest competitor
09 February 2022
Competition law in the pharma sector – Developments and what’s to come in 2022
29 March 2021
CJEU CONFIRMS PAY-FOR-DELAY APPROACH AND UPHOLDS DECISION IN LUNDBECK CASES
04 March 2021
First time EU Commission pursues case relating to divisional patent filing and litigation strategies
16 February 2021
Excessive pricing: EU Commission accepts Aspen’s drug pricing commitments
27 November 2020
The European Commission fines Cephalon and Teva €60.5 million in its fourth “pay-for-delay” decision
27 October 2020
Pharmaceutical sector under increased antitrust scrutiny in the UK
05 June 2020
Advocate General Kokott's Opinion in Lundbeck v Commission
09 April 2020
EU Commission publishes guidance on cooperation arrangements aimed at addressing shortages during the COVID-19 crisis
Showing 22 out of 22 results